Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases-Reference-Cited by-同舟云学术

Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases

Published:2021-09-08 Issue:9 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Martí-Carvajal Arturo J¹²³,De Sanctis Juan Bautista⁴,Dayer Mark⁵,Martí-Amarista Cristina Elena⁶,Alegría Eduardo⁷,Monge Martín Diana⁷,Abd El Aziz Mohamed⁸,Correa-Pérez Andrea⁷⁹,Nicola Susana¹⁰,Parise Vasco Juan Marcos¹⁰

Affiliation:

1. Facultad de Ciencias de la Salud Eugenio Espejo (Centro Cochrane Ecuador); Universidad UTE; Quito Ecuador

2. Facultad de Medicina (Centro Cochrane Madrid); Universidad Francisco de Vitoria; Madrid Spain

3. Cátedra Rectoral de Medicina Basada en la Evidencia; Universidad de Carabobo; Valencia Venezuela

4. The Institute of Molecular and Translational Medicine; Palacky University Olomouc, Faculty of Medicine and Dentistry; Olomouc Czech Republic

5. Department of Cardiology; Somerset NHS Foundation Trust; Taunton UK

6. Department of Family Medicine; Northwell Health Southside Hospital; Bay Shore New York USA

7. Faculty of Medicine; Universidad Francisco de Vitoria; Madrid Spain

8. Internal medicine; Texas Tech University Health Sciences Center El PasoPaul L. Foster School of Medicine; El Paso, Texas USA

9. Clinical Biostatistics Unit; Hospital Universitario Ramón y Cajal (IRYCIS); Madrid Spain

10. Centro Asociado Cochrane Ecuador, Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC); Universidad UTE; Quito Ecuador

Publisher

Wiley

Subject

Pharmacology (medical)

Reference204 articles.

1. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study);Abbate;American Journal Cardiology,2010

2. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study];Abbate;American Journal of Cardiology,2013

3. Interleukin-1 and the Inflammasome as therapeutic targets in cardiovascular disease;Abbate;Circulation Research,2020

4. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction;Abbate;Journal of the American Heart Association,2020